

ENGAGE II

International Workshop on Immunomodulation and Desensitisation

Date: 27-28 November, 2024

Location: Hotel Melia Sky Barcelona
Barcelona, Spain

The European Guidelines for the management of Graft recipients (ENGAGE) is an initiative from the European Society for Organ Transplantation (ESOT).

ENGAGE II working group published an updated definition of sensitization in candidates for solid organ transplantation (Bestard et al., Transpl Int, 2021, 34: 1005–1018) suggesting that data from the patient's "immunological" history should be integrated with single-antigen bead assay and cytotoxic (CDC) and flow cytometry cross-matching, to enable their risk of antibody mediated rejection (AMR) and graft loss to be estimated and stratified into one of five categories.

Building on this first step, the ENGAGE II working group performed a systematic search evaluating the Induction Therapies, Antibody Removal Strategies and New Biological Drugs and Maintenance immunosuppression and these data have been synthesised in a white paper that has been the basis for the rationale of the following step, the ENGAGE consensus project.

The project, based on the Delphi methodology, was aimed at obtaining a consensus among European experts on desensitisation and immunomodulation of kidney recipients, according to defined pre-transplantation patient humoral risk profiles.

Desensitisation strategies are employed before the transplantation to prevent hyperacute rejection in patients with high levels of preformed DSA and therefore increase transplant candidate's access to transplantation. In contrast, the modulation of induction and maintenance immunosuppression (including the use of Antibody Removal Strategies) can be adjusted from day 0 onward according to the risk profile of the recipient in order to reduce his risk of subsequent AMR and graft loss.

The ENGAGE II working group final paper titled "European consensus on the management of sensitised kidney transplant recipients: a Delphi study" has been accepted for publication on Transplant International (TI), in March 2024.

Learning Objectives:

After attending this masterclass participants will learn more about:

- Desensitization and Immunomodulation strategies based on patient risk

Target Audience:

- Nephrologists
- HLA Specialists
- Transplant Surgeons
- Experts in the field of Immunomodulation and Desensitisation



Scientific Organisers:

Lucrezia Furian (Italy)
Olivier Thauinat (France)

Faculty:

Oriol Bestard (Spain)
Georg Böhmig (Austria)
Emanuele Cozzi (Italy)
Delphine Kervella (Spain)
Alice Koenig (France)
Kevin Louis (France)
Maarten Naesens (Belgium)
Søren Schwartz Sørensen (Denmark)
Ondřej Viklický (Czechia)

Reading Materials -

1. [European Consensus on the Management of Sensitized Kidney Transplant Recipients: A Delphi Study](#)

Preliminary Scientific Programme – 27 November 2024

Session 1 Dissemination of ENGAGE II (14:30 – 17:45)

Moderator: Lucrezia Furian (Italy)

14:30	Welcome Address	10 min	Lucrezia Furian (Italy)
14:40	Engage II Conclusions	30 min	Lucrezia Furian (Italy)
15:10	Interactive Case Study: Strata 1	30 min	Alice Koenig (France)
15:40	Interactive Case Study: Strata 2	30 min	Speaker to be confirmed
16:10	Coffee Break	30 min	
16:40	Interactive Case Study: Strata 3	30 min	Kevin Louis (France)
17:10	Interactive Case Study: Strata 4	30 min	Delphine Kervella (Spain)
17:40	Wrap Up	5 min	Lucrezia Furian (Italy)

ESOT Headquarters

Westerdoksdiik 423, 1013 BX Amsterdam, The Netherlands - E: askme@esot.org - W: <https://esot.org/> - T: +393482786092

European Society for Organ Transplantation (ESOT) ESOT is registered as a charity (Algemeen Nut Beogende Instelling: ANBI) in the Netherlands. VAT Registration number NL829509498B01 - Chamber of Commerce Amsterdam Registration number 34329686 - Stichting ESOT is the support foundation of the European Society for Organ Transplantation (ESOT) VAT Registration number NL822162313B01 - Chamber of Commerce Amsterdam Registration number 34385303 - Legal Seat: Westerdoksdiik 423, 1013 BX Amsterdam, The Netherlands

Preliminary Scientific Programme – 28 November 2024

Session 2 Paving the way for ENGAGE III (09:00 – 12:00)

Moderator: Georg Böhmig (Austria), Olivier Thauvat (France)

09:00	Introduction	5 min	Olivier Thauvat (France)
09:05	Pathophysiology of AMR	30 min	Olivier Thauvat (France)
09:35	Present Treatment Options	30 min	Georg Böhmig (Austria)
10:05	Coffee Break	30 min	
10:35	Paving the way for ENGAGE III	60 min	Speakers to be confirmed
11:35	Closing	25 min	Georg Böhmig (Austria) Olivier Thauvat (France)